OP
IMDX

ORG Partners’s Insight Molecular Diagnostics IMDX Stock Holding History

ORG Partners’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$3.38K Hold
450
– – ﹤0.01% 1341
2025
Q3 		$1.49K Sell
450
-650
-59% -$1.83K ﹤0.01% 1349
2025
Q2 		$3.34K Buy
1,100
+650
+144% +$1.96K ﹤0.01% 1115
2025
Q1 		$1.35K Buy
+450
New +$1.22K ﹤0.01% 1131

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ORG Partners's IMDX Position: Q4 2025 in Review

ORG Partners held its Insight Molecular Diagnostics (IMDX) position steady in Q4 2025 at 450 shares worth $3.38K. The position accounts for ﹤0.01% of the portfolio, ranked #1341.

ORG Partners first reported a position in IMDX in Q1 2025 and has held it in 4 quarters since. 35 funds tracked by Wall St. Rank hold IMDX as of Q4 2025.

  • ORG Partners held 450 shares of Insight Molecular Diagnostics worth $3.38K as of Q4 2025.
  • ORG Partners left its Insight Molecular Diagnostics share count unchanged in Q4 2025.
  • Insight Molecular Diagnostics made up ﹤0.01% of ORG Partners's portfolio in Q4 2025, its #1341 holding.
  • ORG Partners first reported a position in Insight Molecular Diagnostics in Q1 2025 and has held it in 4 quarters since.
  • 35 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2025.

Based on ORG Partners's 13F filing for Q4 2025, filed 14 Jan 2026.